Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers ...

Bristol Myers Squibb and Pfizer are launching a direct-to-patient program with 40% discount on Eliquis, reducing the monthly cost from $606 to $346 for eligible patients.

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount.

The drugmakers Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price—a move that follows the Trump administration’s ...

(Reuters) -US drugmakers Bristol Myers (NYSE: BMY) and Pfizer (NYSE: PFE) said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at ...